Loading…

Digital Endpoints: Definition, Benefits, and Current Barriers in Accelerating Development and Adoption

The assessment of health and disease requires a set of criteria to define health status and progression. These health measures are referred to as “endpoints.” A “digital endpoint” is defined by its use of sensor-generated data often collected outside of a clinical setting such as in a patient’s free...

Full description

Saved in:
Bibliographic Details
Published in:Digital biomarkers 2021-09, Vol.5 (3), p.216-223
Main Authors: Landers, Matthew, Dorsey, Ray, Saria, Suchi
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4105-4b0001ddb54067d584a1bcebfc4da38d3dd2f89de084b2cd55d19e1f51676cea3
cites cdi_FETCH-LOGICAL-c4105-4b0001ddb54067d584a1bcebfc4da38d3dd2f89de084b2cd55d19e1f51676cea3
container_end_page 223
container_issue 3
container_start_page 216
container_title Digital biomarkers
container_volume 5
creator Landers, Matthew
Dorsey, Ray
Saria, Suchi
description The assessment of health and disease requires a set of criteria to define health status and progression. These health measures are referred to as “endpoints.” A “digital endpoint” is defined by its use of sensor-generated data often collected outside of a clinical setting such as in a patient’s free-living environment. Applicable sensors exist in an array of devices and can be applied in a diverse set of contexts. For example, a smartphone’s microphone might be used to diagnose or predict mild cognitive impairment due to Alzheimer’s disease or a wrist-worn activity monitor (such as those found in smartwatches) may be used to measure a drug’s effect on the nocturnal activity of patients with sickle cell disease. Digital endpoints are generating considerable excitement because they permit a more authentic assessment of the patient’s experience, reveal formerly untold realities of disease burden, and can cut drug discovery costs in half. However, before these benefits can be realized, effort must be applied not only to the technical creation of digital endpoints but also to the environment that allows for their development and application. The future of digital endpoints rests on meaningful interdisciplinary collaboration, sufficient evidence that digital endpoints can realize their promise, and the development of an ecosystem in which the vast quantities of data that digital endpoints generate can be analyzed. The fundamental nature of health care is changing. With coronavirus disease 2019 serving as a catalyst, there has been a rapid expansion of home care models, telehealth, and remote patient monitoring. The increasing adoption of these health-care innovations will expedite the requirement for a digital characterization of clinical status as current assessment tools often rely upon direct interaction with patients and thus are not fit for purpose to be administered remotely. With the ubiquity of relatively inexpensive sensors, digital endpoints are positioned to drive this consequential change. It is therefore not surprising that regulators, physicians, researchers, and consultants have each offered their assessment of these novel tools. However, as we further describe later, the broad adoption of digital endpoints will require a cooperative effort. In this article, we present an analysis of the current state of digital endpoints. We also attempt to unify the perspectives of the parties involved in the development and deployment of these tools. We conclud
doi_str_mv 10.1159/000517885
format article
fullrecord <record><control><sourceid>proquest_karge</sourceid><recordid>TN_cdi_karger_primary_517885</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_7b8a60c189394032b44edaab79a97880</doaj_id><sourcerecordid>2615274055</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4105-4b0001ddb54067d584a1bcebfc4da38d3dd2f89de084b2cd55d19e1f51676cea3</originalsourceid><addsrcrecordid>eNptks-L1TAQgIso7rLuwbuHwl4U9mnSJm3iQXg_Vn2w4EXBW5gm05pnX9JN2gX_e1O7PFzxlGTmm4_JMFn2kpK3lHL5jhDCaS0Ef5KdF5ywFaXk-9O_7mfZZYyHhFHBSE3L59lZyWpSyro6z9qd7ewIfX7jzOCtG-P7fIetdXa03l3nG3TpNcbrHJzJt1MI6MZ8AyFYDDG3Ll9rjT0GGK3rUuk99n44ztBcsDZ-mEUvsmct9BEvH86L7NvHm6_bz6vbL5_22_XtSjNK-Io1c5vGNJyRqjZcMKCNxqbVzEApTGlM0QppkAjWFNpwbqhE2nJa1ZVGKC-y_eI1Hg5qCPYI4ZfyYNWfgA-dgjBa3aOqGwEV0VTIUjJSFg1jaACaWoJM4yTJ9WFxDVNzRKPTnwL0j6SPM87-UJ2_V4JJIilLgtcPguDvJoyjOtqYhtWDQz9FVXBRSVmxQiT06h_04Kfg0qhUUVFe1Ixwnqg3C6WDjzFge2qGEjUvgzotQ2JfLexPCB2GE3lKX_03vdtvFkINpi1_A11cugE</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2615274055</pqid></control><display><type>article</type><title>Digital Endpoints: Definition, Benefits, and Current Barriers in Accelerating Development and Adoption</title><source>PubMed Central</source><source>Karger Open Access</source><creator>Landers, Matthew ; Dorsey, Ray ; Saria, Suchi</creator><creatorcontrib>Landers, Matthew ; Dorsey, Ray ; Saria, Suchi</creatorcontrib><description>The assessment of health and disease requires a set of criteria to define health status and progression. These health measures are referred to as “endpoints.” A “digital endpoint” is defined by its use of sensor-generated data often collected outside of a clinical setting such as in a patient’s free-living environment. Applicable sensors exist in an array of devices and can be applied in a diverse set of contexts. For example, a smartphone’s microphone might be used to diagnose or predict mild cognitive impairment due to Alzheimer’s disease or a wrist-worn activity monitor (such as those found in smartwatches) may be used to measure a drug’s effect on the nocturnal activity of patients with sickle cell disease. Digital endpoints are generating considerable excitement because they permit a more authentic assessment of the patient’s experience, reveal formerly untold realities of disease burden, and can cut drug discovery costs in half. However, before these benefits can be realized, effort must be applied not only to the technical creation of digital endpoints but also to the environment that allows for their development and application. The future of digital endpoints rests on meaningful interdisciplinary collaboration, sufficient evidence that digital endpoints can realize their promise, and the development of an ecosystem in which the vast quantities of data that digital endpoints generate can be analyzed. The fundamental nature of health care is changing. With coronavirus disease 2019 serving as a catalyst, there has been a rapid expansion of home care models, telehealth, and remote patient monitoring. The increasing adoption of these health-care innovations will expedite the requirement for a digital characterization of clinical status as current assessment tools often rely upon direct interaction with patients and thus are not fit for purpose to be administered remotely. With the ubiquity of relatively inexpensive sensors, digital endpoints are positioned to drive this consequential change. It is therefore not surprising that regulators, physicians, researchers, and consultants have each offered their assessment of these novel tools. However, as we further describe later, the broad adoption of digital endpoints will require a cooperative effort. In this article, we present an analysis of the current state of digital endpoints. We also attempt to unify the perspectives of the parties involved in the development and deployment of these tools. We conclude with an interdependent list of challenges that must be collaboratively addressed before these endpoints are widely adopted.</description><identifier>ISSN: 2504-110X</identifier><identifier>EISSN: 2504-110X</identifier><identifier>DOI: 10.1159/000517885</identifier><identifier>PMID: 34703976</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Accelerometers ; Alzheimer's disease ; Catalysts ; Clinical trials ; Cognitive ability ; Diabetes ; digital endpoints ; digital evidence ; digital medicine ; Digital technology ; Handicapped accessibility ; Health care ; Heart failure ; Innovations ; Laboratories ; Machine learning ; Medical equipment ; Medical technology ; Multiple sclerosis ; Muscular dystrophy ; Parkinson's disease ; Patients ; Physical fitness ; Prescription drugs ; Pulmonary hypertension ; Quality of life ; Quality standards ; Questionnaires ; Sensors ; Smartphones ; Telemedicine ; Viewpoint - Review ; Viewpoint - Review Article</subject><ispartof>Digital biomarkers, 2021-09, Vol.5 (3), p.216-223</ispartof><rights>2021 The Author(s). Published by S. Karger AG, Basel</rights><rights>2021 The Author(s). Published by S. Karger AG, Basel . This work is licensed under the Creative Commons Attribution – Non-Commercial License http://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2021 by S. Karger AG, Basel 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4105-4b0001ddb54067d584a1bcebfc4da38d3dd2f89de084b2cd55d19e1f51676cea3</citedby><cites>FETCH-LOGICAL-c4105-4b0001ddb54067d584a1bcebfc4da38d3dd2f89de084b2cd55d19e1f51676cea3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8490914/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8490914/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27609,27898,27899,53763,53765</link.rule.ids></links><search><creatorcontrib>Landers, Matthew</creatorcontrib><creatorcontrib>Dorsey, Ray</creatorcontrib><creatorcontrib>Saria, Suchi</creatorcontrib><title>Digital Endpoints: Definition, Benefits, and Current Barriers in Accelerating Development and Adoption</title><title>Digital biomarkers</title><addtitle>Digit Biomark</addtitle><description>The assessment of health and disease requires a set of criteria to define health status and progression. These health measures are referred to as “endpoints.” A “digital endpoint” is defined by its use of sensor-generated data often collected outside of a clinical setting such as in a patient’s free-living environment. Applicable sensors exist in an array of devices and can be applied in a diverse set of contexts. For example, a smartphone’s microphone might be used to diagnose or predict mild cognitive impairment due to Alzheimer’s disease or a wrist-worn activity monitor (such as those found in smartwatches) may be used to measure a drug’s effect on the nocturnal activity of patients with sickle cell disease. Digital endpoints are generating considerable excitement because they permit a more authentic assessment of the patient’s experience, reveal formerly untold realities of disease burden, and can cut drug discovery costs in half. However, before these benefits can be realized, effort must be applied not only to the technical creation of digital endpoints but also to the environment that allows for their development and application. The future of digital endpoints rests on meaningful interdisciplinary collaboration, sufficient evidence that digital endpoints can realize their promise, and the development of an ecosystem in which the vast quantities of data that digital endpoints generate can be analyzed. The fundamental nature of health care is changing. With coronavirus disease 2019 serving as a catalyst, there has been a rapid expansion of home care models, telehealth, and remote patient monitoring. The increasing adoption of these health-care innovations will expedite the requirement for a digital characterization of clinical status as current assessment tools often rely upon direct interaction with patients and thus are not fit for purpose to be administered remotely. With the ubiquity of relatively inexpensive sensors, digital endpoints are positioned to drive this consequential change. It is therefore not surprising that regulators, physicians, researchers, and consultants have each offered their assessment of these novel tools. However, as we further describe later, the broad adoption of digital endpoints will require a cooperative effort. In this article, we present an analysis of the current state of digital endpoints. We also attempt to unify the perspectives of the parties involved in the development and deployment of these tools. We conclude with an interdependent list of challenges that must be collaboratively addressed before these endpoints are widely adopted.</description><subject>Accelerometers</subject><subject>Alzheimer's disease</subject><subject>Catalysts</subject><subject>Clinical trials</subject><subject>Cognitive ability</subject><subject>Diabetes</subject><subject>digital endpoints</subject><subject>digital evidence</subject><subject>digital medicine</subject><subject>Digital technology</subject><subject>Handicapped accessibility</subject><subject>Health care</subject><subject>Heart failure</subject><subject>Innovations</subject><subject>Laboratories</subject><subject>Machine learning</subject><subject>Medical equipment</subject><subject>Medical technology</subject><subject>Multiple sclerosis</subject><subject>Muscular dystrophy</subject><subject>Parkinson's disease</subject><subject>Patients</subject><subject>Physical fitness</subject><subject>Prescription drugs</subject><subject>Pulmonary hypertension</subject><subject>Quality of life</subject><subject>Quality standards</subject><subject>Questionnaires</subject><subject>Sensors</subject><subject>Smartphones</subject><subject>Telemedicine</subject><subject>Viewpoint - Review</subject><subject>Viewpoint - Review Article</subject><issn>2504-110X</issn><issn>2504-110X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>M--</sourceid><sourceid>DOA</sourceid><recordid>eNptks-L1TAQgIso7rLuwbuHwl4U9mnSJm3iQXg_Vn2w4EXBW5gm05pnX9JN2gX_e1O7PFzxlGTmm4_JMFn2kpK3lHL5jhDCaS0Ef5KdF5ywFaXk-9O_7mfZZYyHhFHBSE3L59lZyWpSyro6z9qd7ewIfX7jzOCtG-P7fIetdXa03l3nG3TpNcbrHJzJt1MI6MZ8AyFYDDG3Ll9rjT0GGK3rUuk99n44ztBcsDZ-mEUvsmct9BEvH86L7NvHm6_bz6vbL5_22_XtSjNK-Io1c5vGNJyRqjZcMKCNxqbVzEApTGlM0QppkAjWFNpwbqhE2nJa1ZVGKC-y_eI1Hg5qCPYI4ZfyYNWfgA-dgjBa3aOqGwEV0VTIUjJSFg1jaACaWoJM4yTJ9WFxDVNzRKPTnwL0j6SPM87-UJ2_V4JJIilLgtcPguDvJoyjOtqYhtWDQz9FVXBRSVmxQiT06h_04Kfg0qhUUVFe1Ixwnqg3C6WDjzFge2qGEjUvgzotQ2JfLexPCB2GE3lKX_03vdtvFkINpi1_A11cugE</recordid><startdate>20210913</startdate><enddate>20210913</enddate><creator>Landers, Matthew</creator><creator>Dorsey, Ray</creator><creator>Saria, Suchi</creator><general>S. Karger AG</general><general>Karger Publishers</general><scope>M--</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PKEHL</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20210913</creationdate><title>Digital Endpoints: Definition, Benefits, and Current Barriers in Accelerating Development and Adoption</title><author>Landers, Matthew ; Dorsey, Ray ; Saria, Suchi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4105-4b0001ddb54067d584a1bcebfc4da38d3dd2f89de084b2cd55d19e1f51676cea3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Accelerometers</topic><topic>Alzheimer's disease</topic><topic>Catalysts</topic><topic>Clinical trials</topic><topic>Cognitive ability</topic><topic>Diabetes</topic><topic>digital endpoints</topic><topic>digital evidence</topic><topic>digital medicine</topic><topic>Digital technology</topic><topic>Handicapped accessibility</topic><topic>Health care</topic><topic>Heart failure</topic><topic>Innovations</topic><topic>Laboratories</topic><topic>Machine learning</topic><topic>Medical equipment</topic><topic>Medical technology</topic><topic>Multiple sclerosis</topic><topic>Muscular dystrophy</topic><topic>Parkinson's disease</topic><topic>Patients</topic><topic>Physical fitness</topic><topic>Prescription drugs</topic><topic>Pulmonary hypertension</topic><topic>Quality of life</topic><topic>Quality standards</topic><topic>Questionnaires</topic><topic>Sensors</topic><topic>Smartphones</topic><topic>Telemedicine</topic><topic>Viewpoint - Review</topic><topic>Viewpoint - Review Article</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Landers, Matthew</creatorcontrib><creatorcontrib>Dorsey, Ray</creatorcontrib><creatorcontrib>Saria, Suchi</creatorcontrib><collection>Karger Open Access</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Digital biomarkers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Landers, Matthew</au><au>Dorsey, Ray</au><au>Saria, Suchi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Digital Endpoints: Definition, Benefits, and Current Barriers in Accelerating Development and Adoption</atitle><jtitle>Digital biomarkers</jtitle><addtitle>Digit Biomark</addtitle><date>2021-09-13</date><risdate>2021</risdate><volume>5</volume><issue>3</issue><spage>216</spage><epage>223</epage><pages>216-223</pages><issn>2504-110X</issn><eissn>2504-110X</eissn><abstract>The assessment of health and disease requires a set of criteria to define health status and progression. These health measures are referred to as “endpoints.” A “digital endpoint” is defined by its use of sensor-generated data often collected outside of a clinical setting such as in a patient’s free-living environment. Applicable sensors exist in an array of devices and can be applied in a diverse set of contexts. For example, a smartphone’s microphone might be used to diagnose or predict mild cognitive impairment due to Alzheimer’s disease or a wrist-worn activity monitor (such as those found in smartwatches) may be used to measure a drug’s effect on the nocturnal activity of patients with sickle cell disease. Digital endpoints are generating considerable excitement because they permit a more authentic assessment of the patient’s experience, reveal formerly untold realities of disease burden, and can cut drug discovery costs in half. However, before these benefits can be realized, effort must be applied not only to the technical creation of digital endpoints but also to the environment that allows for their development and application. The future of digital endpoints rests on meaningful interdisciplinary collaboration, sufficient evidence that digital endpoints can realize their promise, and the development of an ecosystem in which the vast quantities of data that digital endpoints generate can be analyzed. The fundamental nature of health care is changing. With coronavirus disease 2019 serving as a catalyst, there has been a rapid expansion of home care models, telehealth, and remote patient monitoring. The increasing adoption of these health-care innovations will expedite the requirement for a digital characterization of clinical status as current assessment tools often rely upon direct interaction with patients and thus are not fit for purpose to be administered remotely. With the ubiquity of relatively inexpensive sensors, digital endpoints are positioned to drive this consequential change. It is therefore not surprising that regulators, physicians, researchers, and consultants have each offered their assessment of these novel tools. However, as we further describe later, the broad adoption of digital endpoints will require a cooperative effort. In this article, we present an analysis of the current state of digital endpoints. We also attempt to unify the perspectives of the parties involved in the development and deployment of these tools. We conclude with an interdependent list of challenges that must be collaboratively addressed before these endpoints are widely adopted.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>34703976</pmid><doi>10.1159/000517885</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2504-110X
ispartof Digital biomarkers, 2021-09, Vol.5 (3), p.216-223
issn 2504-110X
2504-110X
language eng
recordid cdi_karger_primary_517885
source PubMed Central; Karger Open Access
subjects Accelerometers
Alzheimer's disease
Catalysts
Clinical trials
Cognitive ability
Diabetes
digital endpoints
digital evidence
digital medicine
Digital technology
Handicapped accessibility
Health care
Heart failure
Innovations
Laboratories
Machine learning
Medical equipment
Medical technology
Multiple sclerosis
Muscular dystrophy
Parkinson's disease
Patients
Physical fitness
Prescription drugs
Pulmonary hypertension
Quality of life
Quality standards
Questionnaires
Sensors
Smartphones
Telemedicine
Viewpoint - Review
Viewpoint - Review Article
title Digital Endpoints: Definition, Benefits, and Current Barriers in Accelerating Development and Adoption
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-25T19%3A49%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_karge&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Digital%20Endpoints:%20Definition,%20Benefits,%20and%20Current%20Barriers%20in%20Accelerating%20Development%20and%20Adoption&rft.jtitle=Digital%20biomarkers&rft.au=Landers,%20Matthew&rft.date=2021-09-13&rft.volume=5&rft.issue=3&rft.spage=216&rft.epage=223&rft.pages=216-223&rft.issn=2504-110X&rft.eissn=2504-110X&rft_id=info:doi/10.1159/000517885&rft_dat=%3Cproquest_karge%3E2615274055%3C/proquest_karge%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4105-4b0001ddb54067d584a1bcebfc4da38d3dd2f89de084b2cd55d19e1f51676cea3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2615274055&rft_id=info:pmid/34703976&rfr_iscdi=true